Paris-based femtech firm Solence, which provides a personalized digital app to support women’s hormonal and metabolic health, specifically targeting Polycystic Ovary Syndrome (PCOS) care, has secured €1.6 million in a seed funding round.
- Established in 2022 by Clara Stephenson and Mael Mertad, Solence develops a digital health application designed to support women with Polycystic Ovary Syndrome (PCOS).
- The app delivers a personalized, multidisciplinary lifestyle intervention program that addresses key factors such as nutrition, physical activity, stress management, sleep, environmental health, and emotional well-being.
- Users track their symptoms regularly, enabling the app to provide tailored guidance and monitor progress. The program is based on clinical research and expert input, offering daily interactive lessons and practical resources to help users manage PCOS symptoms beyond conventional medication.
"We are developing a digital therapy that offers a personalized intervention on the patient's lifestyle and environmental factors to achieve an improvement in her hormonal status and quality of life," claims Clara Stephenson, co-founder and CEO of Solence.
Details of the deal
- The investors in Solence’s €1.6 million seed funding round include Impact Shakers Ventures, BPI France, and several business angels such as Céline Lazorthes, Berthe Latreille, and Stéphane Mardel.
- The fresh capital will enable Solence to deepen product functionality and expand the team to accelerate the development and delivery of its personalized PCOS care solutions.
"Our long-term vision is to leverage the digital phenotype to improve the response to hormonal diseases affecting women, with a view to preventing and promoting their healthy life expectancy. This fundraising is a first step towards making this vision a reality," co-founder and CEO of Solence, Clara Stephenson, commented on LinkedIn.
